neuroscience-psychiatry-2018-posters

Journal of Neurology and Neurorehabilitation Research

Volume 3

Page 42

allied

academies

J u n e 2 8 - 2 9 , 2 0 1 8 | D u b l i n , I r e l a n d

Joint Event on

NEUROSCIENCE AND NEUROLOGICAL DISORDERS

PSYCHIATRY AND PSYCHOLOGICAL DISORDERS

International Conference on

J Neurol Neurorehabil Res 2018, Volume 3

NEWER ADVANCES IN NEUROPSYCHIATRY

Shashita Inamdar

Achieve Concierge, USA

he increasing prevalence of neuropsychiatric disorders in the last 20 years has called for a demand in newdiagnostic and treatment

options. The World Health Organization (WHO) labels mental disorders as a continuing global burden, with an estimated 300

million affected by depression, 60 million affected by bipolar affective disorder, 21 million affected by schizophrenia and 47.5 million

affected by dementia. Conventional methods of using medications to treat such disorders have developed a negative perception

over time among patients and in the media. Most medications are now viewed as having addictive characteristics, short and long-

term side effects, drug interactions, and at times as being ineffective. With resistance from patients and limited efficacy, clinicians

and researchers turn to new and more advanced methods to help those struggling with such disorders. Pharmacogenetics, the

study of the role of the genome in drug interaction and response, has allowed us to better understand why one’s genetic makeup

can enhance or inhibit their response to certain medications. Given insight to the effectiveness of neurotransmitter uptake channels

and transporters or certain metabolism rates, clinicians may make more informed and accurate decisions for their patients. Outside

of pharmacotherapy, many treatments now look to the process of restructuring the brain to aid the symptoms of neuropsychiatric

disorders. Ketamine has gained recent popularity in the treatment of depression and other neuropsychiatric disorders, where it works

at the synaptic level to increase neural connectivity, dendritic remodelling and synaptogenesis for long term effect. Neuromodulation

methods,suchasTranscranialMagneticStimulation(TMS),anFDAcleared,andCEmarkednon-medicationtreatment,Neurofeedback,

an EEG based biofeedback and Hyperbaric Oxygen Therapy (HBOT), have also shown to be leading methods in remodelling the brain

to alleviate symptoms and create long lasting change in the brain structure. By addressing not only the chemical component of the

brain, but also the electrical, we are able to make far more progress in treating neuropsychiatrist disorders and provide many patients

with new hope.